Breaking News on Drug DiscoveryDaily
Wednesday 08 August 2007
Forward to a colleague |
|
|
| Breaking News on Drug Discovery |
||
|
||
| Daily
Wednesday 08 August 2007 |
Forward to a colleague |
|
|
Sponsored Message  Adenoviral shRNA and cDNA collectionsAs the business service unit for Galapagos, a leading genomics-based drug discovery company, BioFocus DPI offers superior adenoviral tools and services to meet your target discovery and validation needs... Click Here Access Full Stories  Biotech firm Archemix strengthens alliancesFollowing Archemix' initial public offering (IPO) filing the company has announced two high profile strategic alliances aimed at leveraging its aptamer technology to a wider audience... Read Abraxis acquires rights to discovery platform Abraxis Bioscience has bought the worldwide rights to a discovery platform designed to generate new therapeutics and identify new drug targets that alter the p53 tumour suppressor signalling pathway... Read Galapagos sees profit drop on spend hike; inks AZ contract Galapagos has reported a profit erosion for the first half of 2007 amidst accelerated R&D spend and business reshuffling. Meanwhile its services division has inked its third contract with AstraZeneca... Read Alzheimer's hits glaucoma between the eyes UK researchers have published results linking the beta amyloid protein associated with Alzheimer's disease to glaucoma, opening up a much needed new target for glaucoma therapies... Read ChanTest to expand ion-channel screening ChanTest has received private equity financing by Ampersand Ventures to enable the company to expand its library of ion channel-expressing cell lines for drug screening... Read |
|
||||||||
All News Headlines for: August | July | June |
||||||||||
 Product OverviewPre-Clinical Contract Research - Free Download Pharmatest offers unique preclinical in vitro and in vivo drug efficacy testing services to pharmaceutical companies developing new drugs against osteoporosis, cancer or osteoarthritis. Our services can also be used for testing existing compounds for possible adverse effects on bone or secondary indication for bone-related diseases, as well as development of functional foods for bone health... Click Here |
||||||||||
|
Related Industry News China declares $1.7bn drug safety investment China has announced an initial $1.7bn investment to bolster its currently questionable ability to effectively monitor the quality of the food and drugs manufactured within its borders... Read Viracept continues to spiral The latest act in the Viracept (nelfinavir) debacle has seen Roche officially lose marketing authorisation for the HIV treatment, following reports of high levels of genotoxic contamination in the drug... Read Pharmaceutical manufacturing: people on the move Amgen, Watson Pharmaceuticals, Abbott, Sigma-Aldrich and BioCryst have all had people on the move in the world of pharmaceutical manufacturing... Read Cambrex profit rises despite flat sales Cambrex has recorded an increase in operating profit in its second quarter financial results despite flat sales... Read
|
||||||||||
|
|||
| Forward to a colleague |
|||
|
To continue to receive this newsletter in your inbox, please add newsletter@DrugResearcher.com to your address book |
|
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved La Tour du Triangle - 26, allee Jules Milhau - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||
